North America Regenerative Medicines Market Size and Forecast (2021 - 2031)
The North America Regenerative Medicines Market is poised for significant growth, with projections indicating that its size will soar to approximately $44.99 billion by 2031, up from $12.12 billion in 2024. This remarkable expansion reflects a compound annual growth rate (CAGR) of 20.8% anticipated between 2025 and 2031.
Overview of the North America Regenerative Medicines Market
The regenerative medicine sector in North America is primarily divided among the United States, Canada, and Mexico, with the U.S. commanding the largest share of the market. The Centers for Disease Control and Prevention (CDC) highlights a critical health issue in the U.S., where a heart attack occurs every 40 seconds, affecting around 805,000 individuals annually. Additionally, cancer remains a leading cause of both morbidity and mortality, imposing substantial healthcare costs and impacting the quality of life for many. The increasing prevalence of chronic and degenerative diseases is driving the demand for innovative treatment modalities, particularly regenerative therapies.
Regenerative medicine offers transformative solutions for prevalent health issues in North America, especially in the realms of cardiovascular diseases, diabetes, and various cancers. Recent advancements in stem cell therapies, gene editing, and tissue engineering are paving the way for new treatment options. Notably, several CAR-T cell therapies have gained FDA approval for the treatment of hematological malignancies, including multiple myeloma and lymphoma, showcasing the potential of regenerative approaches.
Market Segmentation Insights
The North America Regenerative Medicines Market can be categorized based on product type, application, and other factors:
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are responsible for approximately 17.9 million deaths annually. A significant portion of these fatalities arises from heart attacks and strokes, with many occurring prematurely in individuals under 70. Projections indicate that the global prevalence of CVDs could rise by 90% from 2025 to 2050, driven by an aging population, which will also see a 73.4% increase in crude mortality rates.
As the prevalence of CVDs escalates, cardiac surgeries such as coronary artery bypass grafting (CABG) and valve replacements are becoming increasingly common. Reports from the Cleveland Clinic indicate nearly 1,000 isolated CABG surgeries performed in 2024, with lower-than-expected operative mortality rates, underscoring the growing volume of surgeries and improved outcomes. Regenerative therapies, including stem cell treatments and bioengineered tissues, are enhancing heart tissue repair following infarctions or surgical interventions, potentially reducing the need for repeat surgeries and long-term medication.
The incidence of neurodegenerative disorders, particularly Alzheimer's disease (AD), is also on the rise. Approximately 30% of individuals aged 85 and older are affected by AD, contributing to the more than 55 million people globally living with dementia. The National Institutes of Health (NIH) notes that the prevalence of AD increases significantly with age, with cases rising more than 15-fold between the ages of 65 and 85.
Moreover, the demand for regenerative medicine is further fueled by the increasing incidence of musculoskeletal disorders and age-related tissue degeneration. Innovative approaches such as 3D bioprinting and exosome therapies are being explored to enhance recovery and restore function, thereby alleviating the burden of traditional tissue repair surgeries.
As the population ages, dental issues, including tooth loss, are becoming more prevalent, leading to a higher demand for dental procedures that incorporate regenerative medicine. The WHO projects that the global population aged 60 and above will rise from 1 billion in 2020 to 1.4 billion by 2030, and further to 2.1 billion by 2050. This demographic shift, coupled with the increasing rates of gum disease among older adults, underscores the growing need for regenerative therapies in dental care.
Country-Specific Insights
The North American market is primarily driven by the United States, which held the largest market share in 2024. The CDC reported that in 2023, 76.4% of U.S. adults had at least one chronic condition, with over half of these individuals suffering from multiple chronic conditions. The Alzheimer's Association projects that by 2025, over 7.2 million Americans aged 65 and older will be living with Alzheimer's, a number expected to rise to 12.7 million by 2050.
Chronic illnesses such as cardiovascular diseases, cancer, and neurodegenerative disorders often lead to irreversible damage to tissues or organs, making patients ideal candidates for regenerative therapies. These therapies, including stem cell therapy, tissue engineering, and gene therapy, show promise in restoring lost functions and improving patient outcomes. The U.S. government is actively promoting the development of regenerative therapies through regulatory innovations and expedited approval processes, further propelling market growth.
Key Players in the Market
Prominent companies in the Regenerative Medicines Market include Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, BioMarin Pharmaceutical Inc., and others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.
Overview of the North America Regenerative Medicines Market
The regenerative medicine sector in North America is primarily divided among the United States, Canada, and Mexico, with the U.S. commanding the largest share of the market. The Centers for Disease Control and Prevention (CDC) highlights a critical health issue in the U.S., where a heart attack occurs every 40 seconds, affecting around 805,000 individuals annually. Additionally, cancer remains a leading cause of both morbidity and mortality, imposing substantial healthcare costs and impacting the quality of life for many. The increasing prevalence of chronic and degenerative diseases is driving the demand for innovative treatment modalities, particularly regenerative therapies.
Regenerative medicine offers transformative solutions for prevalent health issues in North America, especially in the realms of cardiovascular diseases, diabetes, and various cancers. Recent advancements in stem cell therapies, gene editing, and tissue engineering are paving the way for new treatment options. Notably, several CAR-T cell therapies have gained FDA approval for the treatment of hematological malignancies, including multiple myeloma and lymphoma, showcasing the potential of regenerative approaches.
Market Segmentation Insights
The North America Regenerative Medicines Market can be categorized based on product type, application, and other factors:
- By Product Type: The market is divided into Cell-Based Products, Gene Therapy, and Tissue Engineering, with Tissue Engineering holding the largest market share in 2024.
- By Cell-Based Products: This segment includes Stem Cell and Cell-Based Immunotherapy, where Stem Cell products dominate the market.
- By Application: The market is further segmented into Oncology, Neurological Disorders, Wound Healing and Skin Regeneration, Ophthalmology, Orthopedics and Musculoskeletal, Immunology, Genetic Disorders, and others, with Oncology leading in market share in 2024.
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are responsible for approximately 17.9 million deaths annually. A significant portion of these fatalities arises from heart attacks and strokes, with many occurring prematurely in individuals under 70. Projections indicate that the global prevalence of CVDs could rise by 90% from 2025 to 2050, driven by an aging population, which will also see a 73.4% increase in crude mortality rates.
As the prevalence of CVDs escalates, cardiac surgeries such as coronary artery bypass grafting (CABG) and valve replacements are becoming increasingly common. Reports from the Cleveland Clinic indicate nearly 1,000 isolated CABG surgeries performed in 2024, with lower-than-expected operative mortality rates, underscoring the growing volume of surgeries and improved outcomes. Regenerative therapies, including stem cell treatments and bioengineered tissues, are enhancing heart tissue repair following infarctions or surgical interventions, potentially reducing the need for repeat surgeries and long-term medication.
The incidence of neurodegenerative disorders, particularly Alzheimer's disease (AD), is also on the rise. Approximately 30% of individuals aged 85 and older are affected by AD, contributing to the more than 55 million people globally living with dementia. The National Institutes of Health (NIH) notes that the prevalence of AD increases significantly with age, with cases rising more than 15-fold between the ages of 65 and 85.
Moreover, the demand for regenerative medicine is further fueled by the increasing incidence of musculoskeletal disorders and age-related tissue degeneration. Innovative approaches such as 3D bioprinting and exosome therapies are being explored to enhance recovery and restore function, thereby alleviating the burden of traditional tissue repair surgeries.
As the population ages, dental issues, including tooth loss, are becoming more prevalent, leading to a higher demand for dental procedures that incorporate regenerative medicine. The WHO projects that the global population aged 60 and above will rise from 1 billion in 2020 to 1.4 billion by 2030, and further to 2.1 billion by 2050. This demographic shift, coupled with the increasing rates of gum disease among older adults, underscores the growing need for regenerative therapies in dental care.
Country-Specific Insights
The North American market is primarily driven by the United States, which held the largest market share in 2024. The CDC reported that in 2023, 76.4% of U.S. adults had at least one chronic condition, with over half of these individuals suffering from multiple chronic conditions. The Alzheimer's Association projects that by 2025, over 7.2 million Americans aged 65 and older will be living with Alzheimer's, a number expected to rise to 12.7 million by 2050.
Chronic illnesses such as cardiovascular diseases, cancer, and neurodegenerative disorders often lead to irreversible damage to tissues or organs, making patients ideal candidates for regenerative therapies. These therapies, including stem cell therapy, tissue engineering, and gene therapy, show promise in restoring lost functions and improving patient outcomes. The U.S. government is actively promoting the development of regenerative therapies through regulatory innovations and expedited approval processes, further propelling market growth.
Key Players in the Market
Prominent companies in the Regenerative Medicines Market include Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, BioMarin Pharmaceutical Inc., and others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. REGENERATIVE MEDICINES MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. NORTH AMERICA REGENERATIVE MEDICINES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. REGENERATIVE MEDICINES MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
6.2 North America Regenerative Medicines Market Forecast and Analysis
7. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Cell Based Products
7.1.1 Overview
7.1.2 Cell Based Products: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Gene Therapy
7.2.1 Overview
7.2.2 Gene Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Tissue Engineering
7.3.1 Overview
7.3.2 Tissue Engineering: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY CELL BASED PRODUCTS - PRODUCTS TYPE
8.1 Stem Cell
8.1.1 Overview
8.1.2 Stem Cell: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Based Immuno Therapy
8.2.1 Overview
8.2.2 Cell Based Immuno Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Neurological Disorders
9.2.1 Overview
9.2.2 Neurological Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Wound Healing and Skin Regeneration
9.3.1 Overview
9.3.2 Wound Healing and Skin Regeneration: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Ophthalmology
9.4.1 Overview
9.4.2 Ophthalmology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Orthopedics and Musculoskeletal
9.5.1 Overview
9.5.2 Orthopedics and Musculoskeletal: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.7 Genetic Disorders
9.7.1 Overview
9.7.2 Genetic Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA REGENERATIVE MEDICINES MARKET - COUNTRY ANALYSIS
10.1 North America
10.1.1 North America Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.1.1 North America Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.2.2 United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 United States: North America Regenerative Medicines Market Share - by Product Type
10.1.2.2.2 United States: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.1.2.2.3 United States: North America Regenerative Medicines Market Share - by Application
10.2.3.3 Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 Canada: North America Regenerative Medicines Market Share - by Product Type
10.2.3.3.2 Canada: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.2.3.3.3 Canada: North America Regenerative Medicines Market Share - by Application
10.3.4.4 Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 Mexico: North America Regenerative Medicines Market Share - by Product Type
10.3.4.4.2 Mexico: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.3.4.4.3 Mexico: North America Regenerative Medicines Market Share - by Application
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bristol-Myers Squibb Co
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson & Johnson
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Takeda Pharmaceutical Co Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 BioMarin Pharmaceutical Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 JCR Pharmaceuticals Co. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Daiichi Sankyo Co Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Vertex Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring LLC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Bluebird Bio Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Ferring Pharmaceuticals
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Japan Tissue Engineering Co., Ltd.
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. REGENERATIVE MEDICINES MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. NORTH AMERICA REGENERATIVE MEDICINES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. REGENERATIVE MEDICINES MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
6.2 North America Regenerative Medicines Market Forecast and Analysis
7. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Cell Based Products
7.1.1 Overview
7.1.2 Cell Based Products: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Gene Therapy
7.2.1 Overview
7.2.2 Gene Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Tissue Engineering
7.3.1 Overview
7.3.2 Tissue Engineering: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY CELL BASED PRODUCTS - PRODUCTS TYPE
8.1 Stem Cell
8.1.1 Overview
8.1.2 Stem Cell: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Based Immuno Therapy
8.2.1 Overview
8.2.2 Cell Based Immuno Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA REGENERATIVE MEDICINES MARKET REVENUE ANALYSIS - BY APPLICATION
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Neurological Disorders
9.2.1 Overview
9.2.2 Neurological Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Wound Healing and Skin Regeneration
9.3.1 Overview
9.3.2 Wound Healing and Skin Regeneration: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Ophthalmology
9.4.1 Overview
9.4.2 Ophthalmology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Orthopedics and Musculoskeletal
9.5.1 Overview
9.5.2 Orthopedics and Musculoskeletal: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.7 Genetic Disorders
9.7.1 Overview
9.7.2 Genetic Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA REGENERATIVE MEDICINES MARKET - COUNTRY ANALYSIS
10.1 North America
10.1.1 North America Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.1.1 North America Regenerative Medicines Market Revenue and Forecast and Analysis - by Country
10.1.2.2 United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 United States: North America Regenerative Medicines Market Share - by Product Type
10.1.2.2.2 United States: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.1.2.2.3 United States: North America Regenerative Medicines Market Share - by Application
10.2.3.3 Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 Canada: North America Regenerative Medicines Market Share - by Product Type
10.2.3.3.2 Canada: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.2.3.3.3 Canada: North America Regenerative Medicines Market Share - by Application
10.3.4.4 Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 Mexico: North America Regenerative Medicines Market Share - by Product Type
10.3.4.4.2 Mexico: North America Regenerative Medicines Market Share - by Cell Based Products - Products Type
10.3.4.4.3 Mexico: North America Regenerative Medicines Market Share - by Application
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bristol-Myers Squibb Co
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson & Johnson
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Takeda Pharmaceutical Co Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 BioMarin Pharmaceutical Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 JCR Pharmaceuticals Co. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Daiichi Sankyo Co Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Vertex Pharmaceuticals Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring LLC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Bluebird Bio Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Ferring Pharmaceuticals
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Japan Tissue Engineering Co., Ltd.
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Regenerative Medicines Market Segmentation
Table 2. List of Vendors
Table 3. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 6. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 10. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 13. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 16. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Heat Map Analysis by Key Players
Table 1. North America Regenerative Medicines Market Segmentation
Table 2. List of Vendors
Table 3. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 5. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 6. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 7. North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 9. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 10. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 12. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 13. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 15. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cell Based Products - Products Type
Table 16. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Regenerative Medicines Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Regenerative Medicines Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Regenerative Medicines Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Cell Based Products: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Gene Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Tissue Engineering: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 11. North America Regenerative Medicines Market Share (%) - by Cell Based Products - Products Type, 2024 and 2031
Figure 12. Stem Cell: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Cell Based Immuno Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Regenerative Medicines Market Share (%) - by Application, 2024 and 2031
Figure 15. Oncology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Neurological Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Wound Healing and Skin Regeneration: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Ophthalmology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Orthopedics and Musculoskeletal: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Immunology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Genetic Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Others: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. North America Regenerative Medicines Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 24. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Company Positioning & Concentration
Figure 1. North America Regenerative Medicines Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Regenerative Medicines Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Regenerative Medicines Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Regenerative Medicines Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Cell Based Products: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Gene Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Tissue Engineering: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 11. North America Regenerative Medicines Market Share (%) - by Cell Based Products - Products Type, 2024 and 2031
Figure 12. Stem Cell: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Cell Based Immuno Therapy: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Regenerative Medicines Market Share (%) - by Application, 2024 and 2031
Figure 15. Oncology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Neurological Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Wound Healing and Skin Regeneration: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Ophthalmology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Orthopedics and Musculoskeletal: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. Immunology: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Genetic Disorders: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Others: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. North America Regenerative Medicines Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 24. United States: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Canada: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Mexico: North America Regenerative Medicines Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Company Positioning & Concentration
